{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:18:43Z","timestamp":1776777523003,"version":"3.51.2"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T00:00:00Z","timestamp":1764460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["OP20.05187 RI-SI-EATRIS"],"award-info":[{"award-number":["OP20.05187 RI-SI-EATRIS"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["I0-E011-2022"],"award-info":[{"award-number":["I0-E011-2022"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101057442"],"award-info":[{"award-number":["101057442"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P1-0208"],"award-info":[{"award-number":["P1-0208"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020668","name":"European Research Executive Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cyto.2025.157083","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T10:26:00Z","timestamp":1764757560000},"page":"157083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Drug repurposing for cytokine storm: baricitinib, ciclesonide, and acalabrutinib modulate cytokine release in a translational in vitro lymphoblastoid cell line model"],"prefix":"10.1016","volume":"197","author":[{"given":"Luka","family":"Hiti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tijana","family":"Markovi\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0161a","family":"Kandu\u0161er","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Mlinari\u010d-Ra\u0161\u010dan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2025.157083_bb0005","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2025.157083_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2386","article-title":"Effect of corticosteroid therapy on mortality in COVID-19 patients\u2014a systematic review and meta-analysis","volume":"32","author":"Patel","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.cyto.2025.157083_bb0015","first-page":"339","article-title":"A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms","volume":"20","author":"Langarizadeh","year":"2021","journal-title":"EXCLI J."},{"key":"10.1016\/j.cyto.2025.157083_bb0020","first-page":"243","article-title":"The efficacy and safety of monoclonal antibody treatments against COVID-19: a systematic review and Meta-analysis of randomized clinical trials","volume":"55","author":"Wafa","year":"2023","journal-title":"Acta Med. Indones."},{"key":"10.1016\/j.cyto.2025.157083_bb0025","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/14740338.2021.1946513","article-title":"Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database","volume":"20","author":"Charan","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.cyto.2025.157083_bb0030","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40001-023-01072-z","article-title":"Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis","volume":"28","author":"Dahms","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.cyto.2025.157083_bb0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40246-021-00308-5","article-title":"High heterogeneity undermines generalization of differential expression results in RNA-Seq analysis","volume":"15","author":"Cui","year":"2021","journal-title":"Hum. Genomics"},{"key":"10.1016\/j.cyto.2025.157083_bb0040","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s13059-024-03331-6","article-title":"Overlooked poor-quality patient samples in sequencing data impair reproducibility of published clinically relevant datasets","volume":"25","author":"Sprang","year":"2024","journal-title":"Genome Biol."},{"key":"10.1016\/j.cyto.2025.157083_bb0045","first-page":"ec92","article-title":"New connections: species-specific immune responses","volume":"9","author":"Foley","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.cyto.2025.157083_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867015","article-title":"A comprehensive atlas of immunological differences between humans, mice, and non-human Primates","volume":"13","author":"Bjornson-Hooper","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.157083_bb0055","author":"Animals in science - European Commission"},{"key":"10.1016\/j.cyto.2025.157083_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2023.1185706","article-title":"Advancing the 3Rs: innovation, implementation, ethics and society","volume":"10","author":"Grimm","year":"2023","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.cyto.2025.157083_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2024.12.003","article-title":"The immunopathogenesis of a cytokine storm: the key mechanisms underlying severe COVID-19","volume":"82","author":"Hiti","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cyto.2025.157083_bb0070","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.it.2021.06.001","article-title":"The \u2018cytokine storm\u2019: molecular mechanisms and therapeutic prospects","volume":"42","author":"Karki","year":"2021","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cyto.2025.157083_bb0075","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/toxics12080607","article-title":"Evaluation of THP-1 and Jurkat cell lines Coculture for the in vitro assessment of the effects of immunosuppressive substances","volume":"12","author":"Franko","year":"2024","journal-title":"Toxics"},{"key":"10.1016\/j.cyto.2025.157083_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1331730","article-title":"LMP1 and EBNA2 constitute a minimal set of EBV genes for transformation of human B cells","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.157083_bb0085","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2217\/pgs.11.24","article-title":"Human lymphoblastoid cell lines: a goldmine for the biobankomics era","volume":"12","author":"Nam","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cyto.2025.157083_bb0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2217\/pgs.11.121","article-title":"Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation","volume":"13","author":"Wheeler","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cyto.2025.157083_bb0095","article-title":"Single-cell RNA-seq reveals transcriptomic heterogeneity mediated by host\u2013pathogen dynamics in lymphoblastoid cell lines","volume":"10","author":"SoRelle","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.cyto.2025.157083_bb0100","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00226-19","article-title":"RNA sequencing analyses of gene expression during Epstein-Barr virus infection of primary B lymphocytes","volume":"93","author":"Wang","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.cyto.2025.157083_bb0105","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cell.2019.03.016","article-title":"B cell responses \u2013 cell interaction dynamics and decisions","volume":"177","author":"Cyster","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.cyto.2025.157083_bb0110","doi-asserted-by":"crossref","first-page":"267","DOI":"10.31887\/DCNS.2016.18.3\/dgurwitz","article-title":"Human iPSC-derived neurons and lymphoblastoid cells for personalized medicine research in neuropsychiatric disorders","volume":"18","author":"Gurwitz","year":"2016","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.cyto.2025.157083_bb0115","doi-asserted-by":"crossref","unstructured":"Therapeutics and COVID-19: living guideline, August 2025. Geneva: World Health Organization, 2025. https:\/\/doi.org\/10.2471\/B09540. Licence: CC BY-NC-SA 3.0 IGO.","DOI":"10.2471\/B09540"},{"key":"10.1016\/j.cyto.2025.157083_bb0120","unstructured":"THP-1 - TIB-202 | ATCC, (n.d.). https:\/\/www.atcc.org\/products\/tib-202 (accessed March 21, 2025)."},{"key":"10.1016\/j.cyto.2025.157083_bb0125","unstructured":"Jurkat, Clone E6-1 - TIB-152 | ATCC, (n.d.). https:\/\/www.atcc.org\/products\/tib-152 (accessed March 21, 2025)."},{"key":"10.1016\/j.cyto.2025.157083_bb0130","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2217\/pgs.10.27","article-title":"Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways","volume":"11","author":"Morag","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cyto.2025.157083_bb0135","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s12031-012-9852-z","article-title":"Sex differences in human lymphoblastoid cells sensitivities to antipsychotic drugs","volume":"49","author":"Morag","year":"2013","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.cyto.2025.157083_bb0140","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.toxlet.2014.12.013","article-title":"Characterization of human lymphoblastoid cell lines as a novel in vitro test system to predict the immunotoxicity of xenobiotics","volume":"233","author":"Markovi\u010d","year":"2015","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.cyto.2025.157083_bb0145","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.toxlet.2018.05.022","article-title":"Endocrine disrupting activities and immunomodulatory effects in lymphoblastoid cell lines of diclofenac, 4-hydroxydiclofenac and paracetamol","volume":"294","author":"Klop\u010di\u010d","year":"2018","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.cyto.2025.157083_bb0150","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41419-022-05287-6","article-title":"Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax","volume":"13","author":"Avsec","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cyto.2025.157083_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2001992","article-title":"EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency","volume":"15","author":"Styles","year":"2017","journal-title":"PLoS Biol."},{"key":"10.1016\/j.cyto.2025.157083_bb0160","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cytogfr.2011.10.001","article-title":"Understanding the mechanism of IL-1\u03b2 secretion","volume":"22","author":"Lopez-Castejon","year":"2011","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cyto.2025.157083_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155934","article-title":"Inflammasomes and IL-1 family cytokines in SARS-CoV-2 infection: from prognostic marker to therapeutic agent","volume":"157","author":"Declercq","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2025.157083_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1161067","article-title":"The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions","volume":"14","author":"Carlini","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.157083_bb0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.it.2020.10.012","article-title":"A potential role of interleukin 10 in COVID-19 pathogenesis","volume":"42","author":"Lu","year":"2021","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cyto.2025.157083_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108255","article-title":"The triumvirate of NF-\u03baB, inflammation and cytokine storm in COVID-19","volume":"101","author":"Attiq","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cyto.2025.157083_bb0185","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41440-023-01460-2","article-title":"The role of SARS-CoV-2-mediated NF-\u03baB activation in COVID-19 patients","volume":"47","author":"Zhou","year":"2024","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.cyto.2025.157083_bb0190","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.3390\/ijms23095283","article-title":"The role of nuclear factor kappa B (NF-\u03baB) in development and treatment of COVID-19: review","volume":"23","author":"Gudowska-Sawczuk","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2025.157083_bb0195","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s12275-015-5455-z","article-title":"Characterization of the rapamycin-inducible EBV LMP1 activation system","volume":"53","author":"Kim","year":"2015","journal-title":"J. Microbiol."},{"key":"10.1016\/j.cyto.2025.157083_bb0200","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1038\/onc.2013.565","article-title":"Mechanisms and consequences of constitutive NF-\u03baB activation in B-cell lymphoid malignancies","volume":"33","author":"Nagel","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.cyto.2025.157083_bb0205","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.3390\/v5061587","article-title":"NF-\u03baB and IRF7 pathway activation by Epstein-Barr virus latent membrane protein 1","volume":"5","author":"Ersing","year":"2013","journal-title":"Viruses"},{"issue":"Suppl. 1","key":"10.1016\/j.cyto.2025.157083_bb0210","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1038\/sj.cdd.4401413","article-title":"Glucocorticoid receptor heterozygosity combined with lack of receptor auto-induction causes glucocorticoid resistance in Jurkat acute lymphoblastic leukemia cells","volume":"11","author":"Riml","year":"2004","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.cyto.2025.157083_bb0215","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.cyto.2025.157083_bb0220","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1001\/jama.2021.16438","article-title":"Glucocorticoid dose in COVID-19: lessons for clinical trials during a pandemic","volume":"326","author":"Webb","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cyto.2025.157083_bb0225","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0140-6736(23)02882-9","article-title":"High-dose corticosteroid therapy in COVID-19: the RECOVERY trial","volume":"403","author":"Hashim","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2025.157083_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2023.152378","article-title":"Th-1, Th-2, Th-9, Th-17, Th-22 type cytokine concentrations of critical COVID-19 patients after treatment with Remdesivir","volume":"228","author":"Kalantar","year":"2023","journal-title":"Immunobiology"},{"key":"10.1016\/j.cyto.2025.157083_bb0235","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s11094-024-03066-5","article-title":"In vitro study of the cytotoxic and Immunotropic effects of Molnupiravir and Favipiravir","volume":"57","author":"Brodovskaya","year":"2024","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.cyto.2025.157083_bb0240","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd0110","article-title":"Inhibition of Bruton tyrosine kinase in patients with severe COVID-19","volume":"5","author":"Roschewski","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.cyto.2025.157083_bb0245","doi-asserted-by":"crossref","DOI":"10.1093\/immhor\/vlaf023","article-title":"Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalization","volume":"9","author":"Scheinberg","year":"2025","journal-title":"ImmunoHorizons"},{"key":"10.1016\/j.cyto.2025.157083_bb0250","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00005-014-0309-7","article-title":"Cyclosporine a regulates pro-inflammatory cytokine production in ulcerative colitis","volume":"63","author":"Steiner","year":"2015","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.cyto.2025.157083_bb0255","doi-asserted-by":"crossref","first-page":"pe25","DOI":"10.1126\/scisignal.267pe25","article-title":"Immune regulation by rapamycin: moving beyond T cells","volume":"2","author":"Janes","year":"2009","journal-title":"Sci. Signal."},{"key":"10.1016\/j.cyto.2025.157083_bb0260","unstructured":"Home, Nlgip (n.d.). https:\/\/www.nlgip-yoran.sites.tau.ac.il (accessed March 20, 2025)."},{"key":"10.1016\/j.cyto.2025.157083_bb0265","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1042\/BIO03801006","article-title":"Human lymphoblastoid cell lines: a valuable tool for personalized medicine research","volume":"38","author":"Gurwitz","year":"2016","journal-title":"Biochemist"},{"key":"10.1016\/j.cyto.2025.157083_bb0270","first-page":"987","article-title":"The establishment and applications of the immortal cell banks of Chinese ethnic groups","volume":"54","author":"Yang","year":"2024","journal-title":"SSV"},{"key":"10.1016\/j.cyto.2025.157083_bb0275","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2011-01-332064","article-title":"Human lymphoblastoid B-cell lines reprogrammed to EBV-free induced pluripotent stem cells","volume":"118","author":"Rajesh","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2025.157083_bb0280","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.5966\/sctm.2014-0121","article-title":"Reliable generation of induced pluripotent stem cells from human Lymphoblastoid cell lines","volume":"3","author":"Barrett","year":"2014","journal-title":"Stem Cells Transl. Med."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625002303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625002303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:19:50Z","timestamp":1773865190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466625002303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":56,"alternative-id":["S1043466625002303"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2025.157083","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing for cytokine storm: baricitinib, ciclesonide, and acalabrutinib modulate cytokine release in a translational in vitro lymphoblastoid cell line model","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2025.157083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"157083"}}